Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
Market Analysis and Insights: Global Hormone Refractory Prostate Cancer (HRPCA) Market
The global Hormone Refractory Prostate Cancer (HRPCA) market size is projected to reach US$ 7340.5 million by 2026, from US$ 6960.7 million in 2020, at a CAGR of 5.0%% during 2021-2026.
Global Hormone Refractory Prostate Cancer (HRPCA) Scope and Market Size
Hormone Refractory Prostate Cancer (HRPCA) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hormone Refractory Prostate Cancer (HRPCA) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
...
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Surgery
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
North America
Europe
China
Japan
Southeast Asia
India
Market Analysis and Insights: Global Hormone Refractory Prostate Cancer (HRPCA) Market
The global Hormone Refractory Prostate Cancer (HRPCA) market size is projected to reach US$ 7340.5 million by 2026, from US$ 6960.7 million in 2020, at a CAGR of 5.0%% during 2021-2026.
Global Hormone Refractory Prostate Cancer (HRPCA) Scope and Market Size
Hormone Refractory Prostate Cancer (HRPCA) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hormone Refractory Prostate Cancer (HRPCA) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
...
Market segment by Type, the product can be split into
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Surgery
Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
